10k out--->
"
Also, out-licensing of our stem cell-related intellectual property is an attractive option that we intend to pursue. We also plan attendance at trade shows in 2013 and beyond to expand awareness of our products, technology and business opportunities.
"
"
Products to support stem cell research are also produced and marketed by other companies with substantially greater resources than the Company. Present suppliers of human stem cells and related products include In-Vitrogen/Life Technologies, Inc., Millipore, Stem Cell Technologies and several other firms. Most of these firms have long-standing histories and significant financial resources. Studies completed during 2010 by the Company of our MSC-Gro™ Brand of stem cell media have provided results showing performance advantages of MSC-Gro™ compared to major competitors including In-Vitrogen, Lonza and Stem Cell Technologies, Inc. Several other independent third parties have also provided corroborating evidence showing performance advantages of the Company’s MSC-Gro™ Brand of stem cell media in a variety of applications extending the commercial utility of these products.
We believe our products for use in stem cell and cancer research have competitive features unlike other marketed products. We may be the only commercial source of fluorescent-labeled stem cells. As we develop additional media products, we anticipate comparable competitive advantages since these formulations are based upon the original MSC-Gro™ formulation. We further intend to patent additional products that we may develop providing exclusive use of such products to the Company and its licensees.
"
"
The Company remains committed to a growth strategy based on suitable business combinations with private entities and is engaged in discussions with potential merger/acquisition candidates. The present capital structure of the Company is conducive to acquisition of synergistic private entities operating in comparable business sector to the Company. Management believes that because of the focus of the Company on adult stem cell products and technology together with the strong growth of this industry due numerous demonstrations of clinical efficacy for a variety of indications, both in animals and humans, that there are significant business combination opportunities available to the Company. A goal of our business development program is to identify and pursue suitable business partners as exemplified by our strategic alliance partnerships including HemoGenix®, Inc., Neuromics, Inc, Stemgenesis, Inc and our patent license with Dr. James Posillico. The Company is also pursuing other approaches to increase its capital resources such as investment, further out-licensing of its intellectual property, sale of assets or other transactions that may be appropriate.
"
News 
Market Data 
Discover 
AI
